Google
TVTX — TRAVERE THERAPEUTICS INC (Healthcare >> Biotechnology)
TVTX FAQ
What is TVTX's P/E ratio?
TRAVERE THERAPEUTICS INC (TVTX) currently trades at a P/E ratio of 140.49.
What is TVTX's ROE?
TRAVERE THERAPEUTICS INC reports a Return on Equity (ROE) of -21.70%.
What is TVTX's dividend yield?
TRAVERE THERAPEUTICS INC offers a dividend yield of 0.00%.
What is TVTX's Deepscope Quality Score?
Deepscope rates TVTX's overall financial quality at 54 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy TVTX?
Deepscope's AI Timing Score for TVTX is 87 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does TVTX belong to?
TRAVERE THERAPEUTICS INC is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange.
|
USD 45.20
Price
2.24
(5.21%)
Day Change
|
|
|---|
TVTX, ファンダメンタルスコアはnot quite good ( ファンダメンタル = 54) but テクニカルスコアは ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
P/Eが高い。割高銘柄。
ROEが低い
ROAが低い
平均ROEが低い
NPMが低い
NPMの伸びが低い
NPMの伸びが低い
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
In details, quality factors are not good , financial health is not good , and ability to make profit is not quite good , ...
| Deepscope 分析 |
|
45% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.08 From 30 days period |
| News Score | 85 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 45.20 |
| PBV / Sector |
40.46 / 4.48
|
| Earning Per Share | -0.24 |
| PE / Sector |
140.49 / 16.68
|
| PEG or PE/Growth / Sector |
32.15 / 0.53
|
| Average 1M Daily Value |
102.49 M
GREAT
|
| Average 1W Daily Value |
83.57 M
|
| Timing Factors |
|
57% |
| Financial Health |
|
37% |
| ポイントになる統計 |
|
52% |
| 配当 |
|
4% |
| 登録情報 |
| Analyze Date | 2026-06-04 09:24:06 |
| Symbol | TVTX |
| Name | TRAVERE THERAPEUTICS INC |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 92.99 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 3,994.97 / 8,483.11 |
| ニュース |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 3611 Valley Centre Drive, San Diego, CA, United States, 92130
Phone: 888 969 7879
Website: https://travere.com
Employees: 497
Sector: Healthcare >> Biotechnology
Description: Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases in the United States. The company's products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones. Its clinical-stage programs consist of Sparsentan, a novel investigational product candidate, which has been granted Orphan Drug Designation for the treatment of focal segmental glomerulosclerosis in the U.S. and Europe; and Pegtibatinase, a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria. It has a collaboration agreement with PharmaKrysto Limited for the pre-clinical activities associated with the cystinuria program. Travere Therapeutics, Inc. was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020. The company is headquartered in San Diego, California.
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
